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Abstract
Introduction: Many studies have shown that monocyte human leukocyte antigen-DR (mHLA-DR) expression may
be a good predictor for mortality in severe septic patients. On the contrary, other studies found mHLA-DR was not
a useful prognostic marker in severe sepsis. Few studies have taken changes of mHLA-DR during treatment into
consideration. The objective of this study was to estimate the prognostic value of changes of mHLA-DR to predict
mortality in severe sepsis.
Methods: In this prospective observational study, mHLA-DR was measured by flow cytometry in peripheral blood
from 79 adult patients with severe sepsis. mHLA-DR levels were determined on day 0, 3, 7 after admission to the
surgical intensive care unit (SICU) with a diagnosis of severe sepsis. ΔmHLA-DR3 and ΔmHLA-DR7 were defined as
the changes in mHLA-DR value on day 3 and day 7 compared to that on day 0. Data were compared between
28-day survivors and non-survivors. Receiver operating characteristic (ROC) curves were plotted to measure the
performance and discriminating threshold of ΔmHLA-DR3, ΔmHLA-DR7, ΔmHLA-DR7-3, mHLA-DR0, mHLA-DR3 and
mHLA-DR7 in predicting mortality of severe sepsis.
Results: ROC curve analysis showed that ΔmHLA-DR3 and ΔmHLA-DR7 were reliable indicators of mortality in
severe sepsis. A ΔmHLA-DR3 value of 4.8% allowed discrimination between survivors and non-survivors with a
sensitivity of 89.0% and a specificity of 93.7%; similarly, ΔmHLA-DR7 value of 9% allowed discrimination between
survivors and non-survivors with a sensitivity of 85.7% and a specificity of 90.0%. Patients with ΔmHLA-DR3 ≤4.8%
had higher mortality than those with ΔmHLA-DR3 > 4.8% (71.4% vs. 2.0%, OR 125.00, 95% CI 13.93 to 1121.67);
patients with ΔmHLA-DR7 ≤9% had higher mortality than those with ΔmHLA-DR7 > 9% (52.9% vs. 2.0%, OR 54.00,
95% CI 5.99 to 486.08). The mean change of mHLA-DR significantly increased in the survivor group with the
passage of time; from day 0 to day 3 and day 7, changes were 6.45 and 16.90 (P < 0.05), respectively.
Conclusions: The change of mHLA-DR over time may be a reliable predictor for mortality in patients with severe
sepsis.
Introduction
Severe sepsis is an important cause of admission to inten-
sive care units (ICUs) throughout the world and is charac-
terized by high mortality in adults [1-4]. But the
pathogenesis of sepsis is still not clear. Previous reports
suggest that the depression of the immune system may
contribute to the severity of sepsis. Although the mechan-
istic and molecular bases for ICU-acquired immunosup-
pression are not exhaustively established, several features
of the condition, including enhanced leukocyte apoptosis,
lymphocyte anergy, and deactivated monocyte functions,
have already been described [5-7]. mHLA-DR has been
suggested to be a reliable marker for estimating immuno-
suppression. The level of mHLA-DR was significantly
decreased during severe sepsis [8], although little is known
about the underlying mechanism. The reduced expression
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value for the prognosis of patients with sepsis [9-12] or
the risk of secondary infection [13-16]. However, the asso-
ciation between low mHLA-DR and mortality in severe
sepsis has been challenged [17]. These differences in find-
ings may be partially explained by the fact that immune
function is dynamically changing during the clinical course
of severe sepsis. In this study, we monitored the expres-
sion of mHLA-DR during 1 week to evaluate the predic-
tive power of serial determinations of mHLA-DR as a
marker of mortality in severe sepsis. Our hypothesis was
that ΔmHLA-DR would be more accurate than mHLA-
DR in predicting 28-day mortality in severe sepsis.
Material and methods
Patients
This prospective single-center study was conducted in a
surgical ICU (SICU) with 12 beds of a tertiary, teaching
hospital between June 2008 and August 2010. A total of
107 patients were enrolled. Written informed consent was
obtained from the patients or, for patients unable to pro-
vide consent, from their closest relatives. The study proto-
col was approved by the ethics committee of the hospital.
Inclusion criteria
Inclusion criteria were (a) age of between 18 and 85 years
and (b) admission to the SICU with a diagnosis of severe
sepsis according to criteria of the American College of
Chest Physicians/Society of Critical Care Medicine [18].
Exclusion criteria were (a) being pregnant or lactating;
(b) receiving immunosuppressive therapy such as cyclos-
porine, azothioprine, or cancer-related chemotherapy; (c)
expected survival of fewer than 28 days because of incor-
rectable medical conditions, such as poorly controlled
neoplasm or other end-stage disease; (d) history of bone
marrow, lung, liver, kidney, pancreas, or small bowel
transplantation; and (e) acute pancreatitis with no estab-
lished source of infection.
Study design
Patients were screened on the admission day, and clinical
and biological variables were collected. These included
demographic characteristics (age and gender), microbiolo-
gical findings (primary infection source and the identified
microorganisms), and comorbidities (chronic obstructive
pulmonary disease, chronic heart failure, malignant dis-
eases, and diabetes). The primary outcome variable was
mortality at day 28 (death or survival). The following clini-
cal parameters were recorded: the initial severity as
assessed by the Acute Physiology and Chronic Health Eva-
luation II (APACHE II) [19] and the Sequential Organ
Failure Assessment (SOFA) (score range of 0 to 24) [20]
on days 0 (on the day of ICU admission), 3, and 7. Blood
samples for analysis of mHLA-DR were collected on days
0, 3, and 7, respectively. ΔmHLA-DR3 and ΔmHLA-DR7
were defined as the value change in mHLA-DR on days 3
and 7 compared with that on day 0 (mHLA-DR0), and
ΔmHLA-DR7-3 was defined as the value change in mHLA-
DR on day 7 compared with that on day 3. That is,
ΔmHLA-DR3 = mHLA-DR3 - mHLA-DR0; ΔmHLA-DR7
=m H L A - D R 7 -m H L A - D R 0;a n dΔmHLA-DR7-3 =
mHLA-DR7 - mHLA-DR3.
mHLA-DR measurement by flow cytometry
Expression of cell surface HLA-DR on monocytes was
measured by flow cytometry (EPICSXL; Beckman Coul-
ter, Inc., Fullerton, CA, USA). Staining and cell acquisi-
tion for flow cytometry were performed within 1 hour
after blood sampling. Monoclonal antibodies were used
as follows: CD14-PE (20 μL, clone M5E2; BD Bios-
ciences, San Jose, CA, USA) and HLA-DR-FITC (20 μL,
clone G46-6; BD Biosciences) per 100 μLo fw h o l e
blood. Negative controls were mouse monoclonal anti-
bodies IgG2a-PE (clone G155-178) and IgG2a-FITC
(clone G155-178), which were isotype-matched in accor-
dance with the recommendations of the manufacturer.
Monocytes were characterized on the basis of their
CD14 expression. At least 1,500 monocytes were ana-
lyzed from each sample. Results are expressed as per-
centages of HLA-DR-positive monocytes out of the total
monocyte population.
Statistical analysis
Quantitative variables with normal distribution were
expressed as mean ± standard deviation, and quantitative
variables with non-normal distribution were expressed as
median and interquartile range (IQR). To estimate mean
changes in mHLA-DR for the survivor and non-survivor
groups, as well as corresponding between-group differ-
ences of changes in mHLA-DR, linear mixed models
with random patient effects were employed. This analysis
took into account the clustering of repeated measures in
patients and the baseline (day 0) mHLA-DR and included
all available cases. The survival estimate was based on the
Kaplan-Meier method, and comparisons of survival dis-
tributions were based on the log-rank test. Receiver oper-
ating characteristic (ROC) curves were produced for
ΔmHLA-DR3, ΔmHLA-DR7, ΔmHLA-DR7-3,m H L A -
DR0,m H L A - D R 3,a n dm H L A - D R 7 to determine the dis-
criminating threshold of each parameter. The optimal
cutoff points were determined by maximizing the sum of
sensitivity and specificity. The areas under the ROC
curves (± standard error) were calculated for each para-
meter, and the comparison between AUCs was con-
ducted on ‘fully paired’ case samples in accordance with
the non-parametric approach reported by DeLong and
colleagues [21]. The Pearson chi-square test or Fisher
exact test, as appropriate, was used for categorical data.
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to identify the variables associated with the risk of death
assessed by odds ratios (ORs) and their 95% confidence
intervals (CIs). The variables with a P value of not more
than 0.10 in univariate analysis were entered in the multi-
variate adjusted model. The predictors included demo-
graphic and clinical parameters. Multivariate regression
analysis was then performed for the independent vari-
ables by ‘enter’ method. Given that different ΔmHLA-
DRs were not independent variables, they were entered
into the model separately. A P value of less than 0.05 was
considered statistically significant. The analyses were per-
formed with SPSS software (version 15.0; SPSS Inc.,
Chicago, IL, USA).
Results
Baseline and clinical characteristics of the patients
During the study period, 107 patients with severe sepsis
were admitted to the SICU. Six patients did not meet
the entry criterion regarding age limitation, 20 patients
met at least one exclusion criterion, and 2 patients were
lost to follow-up (Figure 1). Overall, 79 patients were
enrolled in the study (63 males and 16 females). The
ages ranged from 23 to 75 years (average age of 61 ±
13.6 years), APACHE II score within 24 hours of SICU
admission was a median of 19 (IQR 8), and the median
SOFA score was 8 (IQR 5). The most common sites of
infection were lungs and abdomen, accounting for 36
patients (45.6%) and 42 patients (53.2%), respectively.
After admission, 7 patients died within 3 days and 13
other patients died within 7 days, leaving 79, 72, and 66
surviving patients on days 0, 3, and 7, respectively; over-
all 28-day mortality rate was 29.1% (23/79).
Comparison of mHLA-DR expression changes between
survivors and non-survivors
mHLA-DR was significantly increased in the survivor
group with the passage of time. The mean changes from
day 0 to day 3 and day 7 were 6.45 (P = 0.002) and
16.90 (P < 0.001), respectively. It was 10.45 (P <0 . 0 0 1 )
from day 3 to 7. However, the non-survivor group pre-
sented no significant changes in mHLA-DR (P > 0.05).
O nd a y3 ,t h ed i f f e r e n c eo fc h a n g ef r o md a y0t o3i n
mHLA-DR between survivors and non-survivors was
8.14 and was of borderline significance (P = 0.053). On
day 7, the corresponding differences were 12.35 (P =
0.038) from day 0 to 7 and 4.21 (P = 0.423) from day 3
to 7. These findings suggested that the survivors had a
sustained increase in mHLA-DR over time and pre-
sented a significantly increasing tendency compared
with the non-survivors (Table 1).
Prognostic value of the changes of mHLA-DR expression
The areas under the ROC curve (AUCs) of ΔmHLA-DR3,
ΔmHLA-DR7,a n dΔmHLA-DR7-3 for 28-day mortality
were 0.919 (P <0 . 0 0 1 ) ,0 . 9 3 8( P < 0.001), and 0.729 (P =
0.022), respectively; ΔmHLA-DR3, ΔmHLA-DR7,a n d
ΔmHLA-DR7-3 all had high specificity and sensitivity for
prediction of mortality. The AUCs of mHLA-DR0,
mHLA-DR3, and mHLA-DR7 were 0.570 (P > 0.05), 0.629
(P > 0.05), and 0.598 (P > 0.05), respectively. mHLA-DR0,
mHLA-DR3,a n dm H L A - D R 7 all had low specificity for
prediction of mortality but had high sensitivity (Table 2
and Figures 2 and 3). The difference in AUC between
ΔmHLA-DR3 and mHLA-DR3 is 0.289 ± 0.077 (95% CI
0.139 to 0.439, P < 0.001), the difference in AUC between
ΔmHLA-DR7 and mHLA-DR7 is 0.350 ± 0.091 (95% CI
0.172 to 0.528, P < 0.001), and the difference between
ΔmHLA-DR7-3 and mHLA-DR7 is 0.140 ± 0.110 (95% CI
-0.076 to 0.356, P = 0.204).
There was a significant difference in mortality between
patients with ΔmHLA-DR3 of not more than 4.8% (15/21)
and those with ΔmHLA-DR3 of greater than 4.8% (1/51)
(71.4% versus 2.0%, OR 125.00, 95% CI 13.93 to 1,121.67).
Similarly, patients with ΔmHLA-DR7 of not more than 9%
had a higher mortality rate (9/17) than those with
ΔmHLA-DR7 of greater than 9% (1/49) (52.9% versus
2.0%, OR 54.00, 95% CI 5.99 to 486.08), and patients with
ΔmHLA-DR7-3 of not more than 3.5% had a higher mor-
tality rate (8/28) than those with ΔmHLA-DR7-3 of greater
than 3.5% (2/38) (28.6% versus 5.3%, OR 7.20, 95% CI 1.39
to 37.23).
Gender and all ΔmHLA-DRs were entered in the mul-
tivariate regression analysis because their P values were
lower than 0.1 in univariate analysis. Given that different
Figure 1 Trial profile. ICU, intensive care unit.
Wu et al. Critical Care 2011, 15:R220
http://ccforum.com/content/15/5/R220
Page 3 of 8ΔmHLA-DRs were correlated with each other (a cir-
cumstance that would lead to collinearity if they were in
the same model), different ΔmHLA-DRs were entered
into the multivariate logistic regression model sepa-
rately. After being adjusted for gender, the results indi-
cated that ΔmHLA-DR3 (P < 0.001), ΔmHLA-DR7 (P <
0.001), and ΔmHLA-DR7-3 (P = 0.022) were associated
with a higher mortality (Table 3).
Comparison of 28-day mortality in patients grouped by
mHLA-DR expression with 30% as a cutoff value
The 28-day mortality of patients with mHLA-DR
expression of not more than 30% and those greater than
30% on days 0, 3, and 7 was compared, respectively.
There was no significant difference in 28-day mortality
between patients with mHLA-DR expression of not
more than 30% and those greater than 30% on day 0
(50% (5/10) versus 26.1% (18/69), P = 0.120), day 3
(37.5% (3/8) versus 20.3% (13/64), P = 0.364), and day 7
(25.0% (1/4) versus 14.5% (9/62), P = 0.490), although
non-survivors tended to exhibit lower mHLA-DR
expression than survivors.
Discussion
Sepsis is one of the 10 leading causes of death in critically
ill patients in the US. It is the third leading cause of death
among patients in non-coronary ICUs [22,23]. Severe
sepsis develops each year in more than 750,000 people,
215,000 of whom die of the disease [3], and is considered
a disorder partly due to immunosuppression [5]. The diag-
nosis of immunosuppression depends on paraclinical para-
meters because of the absence of specific clinical
symptoms. Among these, monocyte expression of human
leukocyte antigen type DR (HLA-DR) has been shown to
be useful for monitoring immunoparalysis and accepted as
a reliable marker for evaluation of immune function
[8,15,17]. Also, downregulation of mHLA-DR is generally
accepted as a reliable marker for an immune dysfunction
in patients with sepsis [24].
Volk and colleagues [12] were the first to describe
immunoparalysis indicated by mHLA-DR expression in
patients with sepsis. Abundant research has demon-
strated the reduction of mHLA-DR expression in
patients with sepsis [8,9,13]. A recent study indicated
that patients in severe trauma present with a transient
immunosuppression with decreased mHLA-DR expres-
sion. The lack of mHLA-DR recovery between days 3
and 4 and days 1 and 2 is associated with sepsis [25].
Furthermore, the prognostic value of low HLA-DR
expression on monocytes has been elucidated, and the
severity of the sepsis and mortality have been correlated
with low HLA-DR expression [8,10,15,26,27]. In recent
years, it has been shown that patients with sepsis-
induced immunosuppression were at a higher risk to
Table 1 Linear mixed model on the mean (95% confidence interval) changes in mHLA-DR at every measure point in
the survivor and non-survivor groups
Day 0 Day 3 Day 7
Number mHLA-DR Number mHLA-DR Number mHLA-DR ΔmHLA-DR3 ΔmHLA-DR7 ΔmHLA-DR7-3
Survivor 56 62.97
(56.38~69.55)
56 69.42
(62.92~75.92)
56 79.87
(73.96~85.78)
6.45
a
(2.50~10.40)
16.90
b
(11.85~21.95)
10.45
c
(6.19~14.71)
Non-survivor 23 56.77
(46.49~67.05)
16 55.08
(44.26~65.90)
10 61.32
(49.79~72.84)
-1.69
d
(-8.95~5.57)
4.55
e
(-5.96~15.06)
6.24
f
(-3.28~15.76)
Between-
groups difference
8.14
g
(-0.12~16.40)
12.35
h
(0.70~24.00)
4.21
i
(-6.21~14.64)
ΔmHLA-DR3 and ΔmHLA-DR7 were defined as the value change in mHLA-DR on days 3 and 7 compared with that on day 0, and ΔmHLA-DR7-3 was defined as the
value change in mHLA-DR on day 7 compared with that on day 3. In the comparison of mean mHLA-DR differences in the same group between every
measurement point, P values were
a0.002,
b < 0.001,
c < 0.001,
d0.644,
e0.392, and
f0.195. In the comparison of ΔmHLA-DR differences between two groups within
the same measurement point, P values were
g0.053,
h0.038, and
i0.423. CI, confidence interval; mHLA-DR, monocyte human leukocyte antigen-DR.
Table 2 Predictive value for 28-day mortality of ΔmHLA-DR and mHLA-DR
Number of
patients
Variables Cutoff
value
Sensitivity Specificity Positive
predictive value
Negative
predictive value
AUC 95% CI P value
72 ΔmHLA-DR3 4.8% 89.0% 93.7% 70.9% 98.0% 0.919 ± 0.032 0.83-0.97 < 0.001
66 ΔmHLA-DR7 9.0% 85.7% 90.0% 60.5% 97.2% 0.938 ± 0.030 0.851-0.982 < 0.001
66 ΔmHLA-
DR7-3
3.5% 66.1% 80.0% 37.1% 92.9% 0.729 ± 0.079 0.573-0.884 0.022
79 mHLA-DR0 35.0% 89.1% 43.5% 62.1% 79.3% 0.570 ± 0.070 0.453-0.682 0.319
72 mHLA-DR3 39.5% 91.1% 37.5% 54.6% 83.6% 0.629 ± 0.075 0.508-0.740 0.116
66 mHLA-DR7 47.0% 94.6% 30.0% 49.8% 88.3% 0.598 ± 0.094 0.460-0.708 0.376
ΔmHLA-DR3 and ΔmHLA-DR7 were defined as the value change in mHLA-DR on days 3 and 7 compared with that on day 0, and ΔmHLA-DR7-3 was defined as the
value change in mHLA-DR on day 7 compared with that on day 3; mHLA-DR0, mHLA-DR3, and mHLA-DR7 were defined as the value of mHLA-DR on days 0, 3,
and 7. AUC, area under the curve; CI, confidence interval; mHLA-DR, monocyte human leukocyte antigen-DR.
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gle-center observational trial, Landelle et al.f o u n dt h a t
persistently low mHLA-DR expression is independently
associated with the development of nosocomial infec-
tions [14,28]. Monocyte HLA-DR expression has also
been successfully applied to monitor immunomodula-
tory therapies, including medications such as granulo-
cyte/macrophage colony-stimulating factor (GM-CSF)
[29,30], filgrastim [31], thymosin alpha 1 [32], and inter-
feron-gamma [33], as well as extracorporeal immune
interventions such as immunoadsorption treatment and
continuous hemodiafiltration [34,35].
In contrast, other research suggested that mHLA-DR
was not a useful prognostic marker for outcome. A sin-
gle-center study showed no significant difference in mor-
tality between patients with low HLA-DR expression and
those with normal HLA-DR expression [17]. That study
indicated that mHLA-DR did not give satisfactory discri-
minatory power to assist in an outcome prediction.
Another study reported that the low HLA-DR expression
was not an independent outcome predictor, because the
correlation between outcome and early HLA-DR expres-
sion disappeared after adjustment of the severity of ill-
ness by Sequential Organ Failure Assessment score or
Simplified Acute Physiology Score II [13]. The contradic-
tory results prompt clinicians to seek a more representa-
tive index for the connection between immune status
and outcomes.
Although a number of recent studies have adopted
static HLA-DR expression as a predictive marker, few of
them have addressed the changes of HLA-DR expres-
sion during the disease progress. To address the fact
Figure 2 Receiver operating characteristic (ROC) of ΔmHLA-DR3, ΔmHLA-DR7, and ΔmHLA-DR7-3. ROC analysis depicted the discriminating
value of (a) ΔmHLA-DR3, (b) ΔmHLA-DR7, and (c) ΔmHLA-DR7-3 for 28-day mortality in severe sepsis. ΔmHLA-DR3 and ΔmHLA-DR7 were defined
as the value change in mHLA-DR on days 3 and 7 compared with that on day 0, and ΔmHLA-DR7-3 was defined as the value change in mHLA-
DR on day 7 compared with that on day 3. mHLA-DR, monocyte human leukocyte antigen-DR.
Figure 3 Survival curves of ΔmHLA-DR. Comparison of 28-day mortality by means of Kaplan-Meier survival curves for (a) patients with
ΔmHLA-DR3 of greater than 4.8% (continuous line) and ΔmHLA-DR3 of not more than 4.8% (dashed line), (b) patients with ΔmHLA-DR7 of
greater than 9% (continuous line) and ΔmHLA-DR7 of not more than 9% (dashed line), and (c) patients with ΔmHLA-DR7-3 of greater than 3.5%
(continuous line) and ΔmHLA-DR7-3 of not more than 3.5% (dashed line). ΔmHLA-DR3 and ΔmHLA-DR7 were defined as the value change in
mHLA-DR on days 3 and 7 compared with that on day 0, and ΔmHLA-DR7-3 was defined as the value change in mHLA-DR on day 7 compared
with that on day 3. mHLA-DR, monocyte human leukocyte antigen-DR.
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severe sepsis and to compensate for the drawbacks of
previous studies, we measured the expression of mHLA-
DR consecutively to find out whether its change over
time could predict mortality.
Our results indicated that mHLA-DR was significantly
increased in the survivor group with the passage of
time, but not in the non-survivor group. The findings
were similar to those of Monneret and colleagues [27].
In a study in septic shock, they found that mHLA-DR
expressions were not significantly different between sur-
vivors and non-survivors at days 1 and 2. However, at
days 3 and 4, the mHLA-DR expression had increased
in survivors, but not in non-survivors.
We found that the AUCs of mHLA-DR3 and mHLA-
DR7 for 28-day mortality in patients with severe sepsis
were 0.629 and 0.598, respectively, with low specificity
despite the relatively high sensitivity. In contrast, ΔmHLA-
DR was a good predictor for the outcome of severe sepsis.
Among patients with severe sepsis, those with increased
ΔmHLA-DR expression higher than threshold had mark-
edly lower mortality. ROC curve analysis showed that
ΔmHLA-DR3 and ΔmHLA-DR7 were reliable indicators of
mortality in severe sepsis with high sensitivity and specifi-
city. Multivariate logistic regression analysis showed that
ΔmHLA-DR3, ΔmHLA-DR7, and ΔmHLA-DR7-3 were all
associated with a higher mortality. However, the wide
range of CIs implied poor precision because of the rela-
tively small size of the cohort. It was also found that
ΔmHLA-DR7-3 was not as good as ΔmHLA-DR7 and
ΔmHLA-DR3 either in predicting mortality or in repre-
senting the difference in change of mHLA-DR between
survivors and non-survivors. A possible explanation is that
ΔmHLA-DR3 and ΔmHLA-DR7 are calculated from a
baseline on day 0 but that ΔmHLA-DR7-3 is calculated
from a baseline on day 3, meaning that ΔmHLA-DR7-3 is
affected by more confounding factors such as the treat-
ment in the ICU, the deterioration or improvement of dis-
ease, and other conditions that have impacts on immune
status. Overall, our study suggests that elevated ΔmHLA-
DR expression (especially ΔmHLA-DR3 and ΔmHLA-
DR7) may be seen as a marker for a gradually recovering
immune function during the course of severe sepsis or a
positive response to treatment and may indicate a better
outcome.
A threshold of 30% is retained to predict mortality in
published research that showed that non-survivors had an
expression of mHLA-DR of lower than 30% [9,36]. How-
ever, in this study, there was no significant difference in
28-day mortality between patients with mHLA-DR expres-
sion of not more than 30% and those greater than 30% on
days 0, 3, and 7, although non-survivors tended to exhibit
lower mHLA-DR expression than survivors. At the same
time, the present study found that mean expression of
mHLA-DR in non-survivors was about 60%. This finding
may be explained by the following facts: (a) our study
included only surgical patients, who may have a relatively
minor degree of immunosuppression compared with other
Table 3 Univariate and multivariate logistic regression analysis used to differentiate survivors and non-survivors
Univariate (n = 66) Multivariate (n = 66)
OR 95% CI P value OR 95% CI P value
Gender Male 1.00 - -
Female 5.22 1.25-21.82 0.023 8.19
a 0.75-89.05 0.084
4.56
b 0.65-31.81 0.126
5.47
c 1.15-25.99 0.033
Age, years ≤62 1.00 - -
> 62 2.51 0.59-10.69 0.214
APACHE II
score
≤18 1.00 - -
> 18 2.53 0.63-9.89 0.192
SOFA score ≤7 1.00 - -
> 7 2.02 0.48-8.63 0.341
ΔmHLA-DR3 > 4.8 1.00 - - -
≤4.8 75.00 8.04-699.44 < 0.001 94.71
a 7.64-1174.27 < 0.001
ΔmHLA-DR7 > 9 1.00 - -
≤9 54.00 5.99-486.08 < 0.001 51.04
b 5.35-486.94 < 0.001
ΔmHLA-DR7-3 > 3.5 1.00
≤3.5 7.20 1.39-37.23 0.019 7.46
c 1.34-41.39 0.022
aΔmHLA-DR3,
bΔmHLA-DR7, and
cΔmHLA-DR7-3 were entered into multivariate logistic regression model separately with adjustment of gender. ΔmHLA-DR3 and
ΔmHLA-DR7 were defined as the value change in mHLA-DR on days 3 and 7 compared with that on day 0, and ΔmHLA-DR7-3 was defined as the value change in
mHLA-DR on day 7 compared with that on day 3. APACHE II, Acute Physiology and Chronic Health Evaluation II; CI, confidence interval; OR, odds ratio; SOFA,
Sequential Organ Failure Assessment.
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ensure that severe sepsis was the most likely cause for
patients’ immunosuppression in our study, we had
excluded severely immnunosuppressed patients caused by
other factors, including post-transplantation status and
immunosuppressive therapy. It is assumed that different
patient populations and selection criteria as well as the
heterogeneity of septic host [8] may contribute to the var-
ied findings in different studies. Given the mixed results in
different studies, a fixed static value of HLA-DR may not
be appropriate to be applied in all patient populations and
the dynamic change of HLA-DR seems more reasonable
as an index for mortality.
The present study has certain limitations that need to be
taken into account. This is a single-center study with a
relatively small cohort, and the findings need to be con-
firmed by a multicenter study. In our study, mHLA-DR
was expressed as percentages of HLA-DR-positive mono-
cytes in the total monocyte population, and the measure-
ment was reported to be reproducible with coefficients of
variation from precision studies less than 5% [37]. In spite
of this, the value of delta HLA-DR should be separately
interpreted because we cannot exclude the variability of
measurements by flow cytometry. With the development
of techniques, quantitative flow cytometry offers a better
means of standardization within and between flow cyt-
ometers [38]. With this method, results become compar-
able among different laboratories.
Given these limitations, our objective is not to establish
a golden standard about delta mHLA-DR for predicting
severe sepsis mortality considering the small cohort and
heterogeneity in severe sepsis but to remind clinicians that
the dynamic change of mHLA-DR may be a better para-
meter than static values in judging prognosis and evaluat-
ing efficacy of immunomodulatory therapies. Actually,
similar indices such as delta central venous pressure, delta
stroke volume, and lactate clearance are being widely used
in the ICU.
Conclusions
Our findings demonstrate that, in severe sepsis, moni-
toring the changes of mHLA-DR over time might be
beneficial to predict mortality in comparison with a sin-
gle measurement of mHLA-DR. This may help to iden-
tify patients at increased risk of death.
Key messages
￿ Whether mHLA-DR expression is a good predictor
for mortality in patients with severe sepsis is
controversial.
￿ In this prospective observational study, we moni-
tored the changes of mHLA-DR expression in
patients with severe sepsis.
￿ Our findings demonstrate that, in severe sepsis,
monitoring the changes of mHLA-DR may be a bet-
ter way to predict mortality than taking a single
measurement of mHLA-DR.
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